MEDPLUS

Medplus Health Services Limited
Micro-capPharma ↗

What the six lenses say about MEDPLUS — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹659.7
2026-09-08
VWAP · 1Y anchor
₹811
-18.7% from VWAP
P/E · TTM
36.0×
TTM EPS ₹18.3
52-week range
3%
position low→high
RSI(14)
39
momentum

Own sector index

Pharma ↗
Overweight

1M

+0.4%

3M

+10.5%

1Y

+22.0%

Breadth >EMA21

56%

How MEDPLUS’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
3.0
avg conviction decile
Leadership
—
top-decile composite in cohort
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Micro-cap cohortDRaw
TechnicalD23›

The actual numbers

Price vs VWAP (1y)-18.7%
EMA trend stackDown · 21<50<200
Price vs 200-EMA-16.9%
Price vs 50-EMA-8.5%
RSI(14)39
RS vs Nifty 500 · 3M-27.0%
RS vs sector · 3M-33.0%
52-week range3%
Volume vs 30d avg0.39×
Volume vs 60d avg0.32×
ATR(14) · volatility22.7
Bollinger width · vol contraction0.072
FundamentalD434›

The actual numbers

Return on equity (ROE)11.1%
Operating margin5.7%
Net margin3.2%
Revenue growth · YoY+12.3%
EPS growth · YoY+45.7%
Debt / equity0.72×

Full 8-quarter history in the financials table below.

ValuationD744›

The actual numbers

P/E (TTM)36.0×
TTM EPS₹18.3
52-week range3%
CatalystD537›

The actual numbers

Earnings & momentum25
Capital actions26
Governance272

Every filing in the corporate-announcements panel below.

FlowD450›

The actual numbers

Promoter holding40.2%
Delivery · 30d avg60.3%
Up/down-day asymmetry-3.5pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Micro-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D2 + D4 ) ÷ 2 = 3.0(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Below threshold
7
Conviction score 7/100 · avg-decile strength 3.0/10

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-09-08.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
-2.0pp
-0.6pp
-0.9pp
-25.4pp
-18.9pp
-17.0pp
Nifty 500
Broad-market baseline
-2.0pp
-0.6pp
-2.0pp
-27.0pp
-24.6pp
-22.2pp
Sector
Own-sector index
—
—
-4.8pp
-33.0pp
-37.7pp
-43.0pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

MEDPLUS daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
659.70-16.65

Relative strength

RS vs baseline · rebased to 100

MEDPLUS ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
91.66-1.92

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)1,4891,5761,5611,5101,5431,6791,8061,864
↳ change QoQ—+5.9%-0.9%-3.3%+2.2%+8.8%+7.6%+3.2%
EBITDA (₹cr)102136145136131149159169
EBITDA margin6.9%8.6%9.3%9.0%8.5%8.9%8.8%9.1%
PAT (₹cr)1439465142565864
↳ change QoQ—+169.8%+18.5%+11.2%-17.6%+33.3%+3.6%+10.3%
Net margin1.0%2.5%2.9%3.4%2.7%3.3%3.2%3.4%
EPS (₹)1.203.243.844.293.544.634.825.33
D/E————————
YoY growth · Mar '26Revenue +23.4% YoYPAT +25.5% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

…and 5 more.

Ownership

Who holds MEDPLUS

Mutual funds holding MEDPLUS (10)

FundWeightAUM ₹crGrade
SBI ELSS Tax Saver Reg Gr0.89%32,300
Franklin India Flexi Cap Gr0.62%19,509
Kotak Small Cap Reg Gr1.33%18,933
Franklin India Small Cap Gr1.15%14,467
Nippon India Pharma Gr2.69%9,279
Nippon India Pharma Bns2.69%9,279
ICICI Pru Pharma Healthcare Diag Gr3.80%6,803
Franklin India Mlt-Asst Allc Reg Gr0.82%2,890
Baroda BNP P Hlth and Wellness RegGr1.09%519
ITI Pharma and Healthcare Reg Gr0.88%263

ETFs holding MEDPLUS (0)

No tracked ETF holds MEDPLUS ≥0.5%.

Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma